Boardroom Alpha
Meeting calendar
IPAR · Annual meeting · Tuesday, September 15, 2026

Interparfums Inc

9 nominees · 3 ballot items.

Election of nine directors; advisory (non-binding) vote to approve executive compensation (say-on-pay); and approval to extend the term of the 2016 Stock Option Plan by ten years to 2036.

Market cap
$4.0B
1Y TSR
-3.8%
Board grade
B+
Record date
Jul 22, 2026
Filing
DEF 14A
Filed Jul 31, 2026 · DEF 14A
Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect a Board of Directors consisting of nine (9) members to hold office until the next annual meeting and until their successors are elected and qualified; includes seven incumbent nominees and two proposed new directors (Valerie Hermann and Bénédicte Epinay).

  2. 2

    Advisory Resolution to Approve Executive Compensation (Say-on-Pay

    ManagementBoard: FOR

    Non-binding, advisory vote to approve the compensation paid to the company’s named executive officers as disclosed in the Compensation Discussion and Analysis, compensation tables and related narrative in the proxy statement.

    More detail

    This proposal asks shareholders to cast a non-binding advisory vote to approve the company’s disclosed executive compensation for named executive officers. Management frames the vote as a routine 'say-on-pay' required under Dodd-Frank and stresses that the Compensation Committee has designed pay arrangements to align executive incentives with long-term shareholder interests, combining base salary, discretionary bonuses and long-term equity-based awards. The Board seeks a positive endorsement to reinforce its approach to executive pay, citing the Compensation Committee’s view that compensation is market-competitive and targeted to retain and motivate key executives. Although the vote is advisory and not legally binding, the Board and Compensation Committee state they will consider the outcome when shaping future pay decisions. The company notes historical context that the prior advisory vote in 2025 was overwhelmingly approved, which management interprets as shareholder support for existing practices. From a governance standpoint, shareholders should weigh the advisory nature, the company’s governance structures (an independent Compensation Committee) and potential conflicts given long-tenured executive-shareholders who also receive fees through holding companies. The proposal provides transparency through CD&A and compensation tables, but investors may evaluate pay-for-performance alignment given the company’s recent financial results and dividend policy. The Board’s recommendation to vote FOR is based on its judgment that current compensation policies support retention, performance and alignment with shareholder value creation. Given the non-binding nature, a strong vote against would typically trigger engagement and potential revisions by the Compensation Committee; a strong vote for provides endorsement of current practice.

  3. 3

    Approve Ten-Year Extension of the 2016 Stock Option Plan

    ManagementBoard: FOR

    Vote to adopt an amendment extending the term of the 2016 Stock Option Plan for ten years so that options may be granted through June 27, 2036 (extension of the plan term).

    More detail

    This management proposal requests shareholder approval to amend and extend the term of the company's 2016 Stock Option Plan by ten years because the plan expired on June 27, 2026. Management argues that the plan is a key tool to attract and retain directors, officers, key employees and consultants and to align their interests with shareholders by granting incentive and nonqualified stock options and stock appreciation rights. The amendment does not seek to increase the aggregate share reserve or materially change eligibility or benefits; it solely extends the period during which awards may be granted, preserving the plan's existing structure and administrative provisions. The plan permits up to 1,000,000 shares (subject to anti-dilution adjustments) and currently has 451,535 shares available for future grants, and nonemployee directors receive automatic annual option grants under specified terms. The Board and a committee of independent directors administer the plan, and the proposal notes tax and Section 162(m) considerations, including that certain awards may qualify as performance-based compensation. Shareholder approval is required under the charter to extend the grant period, and the Board emphasizes that affiliates intend to vote in favor and that approval requires a majority of votes cast at the meeting. From a governance perspective, investors should weigh the retention and incentive benefits against potential dilution from additional awards and consider the company’s disclosure around allocation, vesting, repooling of returned shares, and share usage. The Board’s unanimous recommendation and the explicit detail about limits and administration reduce some governance risk, but investors may still evaluate grant practices, overlap with Interparfums SA plans, and historical grant pacing before supporting the extension.

Director elections

Nominees on the ballot9

Not independent
Tenure on this board
34.9 yrs
Valerie Hermann
Independent
Tenure on this board
New nominee
Bénédicte Epinay
Independent
Tenure on this board
New nominee
Ownership

Top institutional holders10

Latest 13F quarter
1BlackRock, Inc.6.0%1,928,292$175M
2VANGUARD PORTFOLIO MANAGEMENT LLC4.0%1,265,390$115M
3WESTWOOD HOLDINGS GROUP INC3.1%1,005,594$91M
4FIRST TRUST ADVISORS LP2.7%879,005$80M
5ROYCE ASSOCIATES LP2.6%822,960$75M
6VANGUARD CAPITAL MANAGEMENT LLC2.5%788,321$72M
7DIMENSIONAL FUND ADVISORS LP2.3%728,464$66M
8STATE STREET CORP2.2%708,298$64M
9MORGAN STANLEY2.1%656,562$60M
10CHARLES SCHWAB INVESTMENT MANAGEMENT INC2.0%641,734$58M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Interparfums Inc 2026 annual meeting?
Interparfums Inc (IPAR) holds its 2026 annual shareholder meeting on Tuesday, September 15, 2026.
What is the record date for the Interparfums Inc 2026 meeting?
The record date for the Interparfums Inc 2026 meeting is Wednesday, July 22, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Interparfums Inc's 2026 meeting?
The board is presenting 9 director nominees at the Interparfums Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Interparfums Inc 2026 meeting?
Shareholders will vote on 3 proposals at the Interparfums Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer